Robert Andrade is CHIEF FINANCIAL OFFICER of FENNEC PHARMACEUTICALS INC.. Currently has a direct ownership of 127,381 shares of FENC, which is worth approximately $677,666. The most recent transaction as insider was on Nov 18, 2024, when has been sold 15,816 shares (Common Shares) at a price of $2.45 per share, resulting in proceeds of $38,749. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 127K
17.47% 3M change
2.13% 12M change
Total Value Held $677,666

Robert Andrade Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 18 2024
BUY
Exercise of conversion of derivative security
$38,749 $2.45 p/Share
15,816 Added 11.04%
127,381 Common Shares
Oct 31 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.93%
111,565 Common Shares
Sep 30 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.93%
110,523 Common Shares
Aug 31 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.94%
109,481 Common Shares
Jul 31 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.95%
108,439 Common Shares
Jul 01 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.96%
107,397 Common Shares
May 31 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.97%
106,355 Common Shares
Apr 30 2024
BUY
Grant, award, or other acquisition
-
1,042 Added 0.98%
105,313 Common Shares
Apr 01 2024
BUY
Open market or private purchase
-
12,500 Added 10.7%
104,271 Common Shares
Mar 26 2024
SELL
Open market or private sale
$152,327 $10.9 p/Share
13,975 Reduced 13.22%
91,771 Common Shares
Mar 25 2024
SELL
Open market or private sale
$153,725 $11.0 p/Share
13,975 Reduced 11.67%
105,746 Common Shares
Jan 05 2024
SELL
Open market or private sale
$156,150 $10.41 p/Share
15,000 Reduced 11.13%
119,721 Common Shares
Jan 04 2024
SELL
Open market or private sale
$159,600 $10.64 p/Share
15,000 Reduced 10.02%
134,721 Common Shares
Jun 30 2023
SELL
Open market or private sale
$66,150 $8.82 p/Share
7,500 Reduced 5.67%
124,721 Common Shares
Jun 30 2023
BUY
Exercise of conversion of derivative security
$61,250 $2.45 p/Share
25,000 Added 14.31%
149,721 Common Shares
Jun 29 2023
SELL
Open market or private sale
$67,275 $8.97 p/Share
7,500 Reduced 5.37%
132,221 Common Shares
Jun 28 2023
SELL
Open market or private sale
$89,900 $8.99 p/Share
10,000 Reduced 6.68%
139,721 Common Shares
Dec 30 2022
SELL
Open market or private sale
$52,855 $9.61 p/Share
5,500 Reduced 3.54%
149,721 Common Shares
Dec 29 2022
SELL
Open market or private sale
$52,635 $9.57 p/Share
5,500 Reduced 3.42%
155,221 Common Shares
Dec 28 2022
SELL
Open market or private sale
$105,710 $9.61 p/Share
11,000 Reduced 6.41%
160,721 Common Shares
Sep 21 2022
SELL
Sale (or disposition) back to the issuer
$162,704 $8.54 p/Share
19,052 Reduced 9.99%
171,721 Common Shares
Sep 21 2022
BUY
Grant, award, or other acquisition
-
37,500 Added 16.43%
190,773 Common Shares
RA

Robert Andrade

CHIEF FINANCIAL OFFICER
Research Triangle Park, NC

Track Institutional and Insider Activities on FENC

Follow FENNEC PHARMACEUTICALS INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells FENC shares.

Notify only if

Insider Trading

Get notified when an Fennec Pharmaceuticals Inc. insider buys or sells FENC shares.

Notify only if

News

Receive news related to FENNEC PHARMACEUTICALS INC.

Track Activities on FENC